The relationship between transforming growth factor-β with erythema nodosum leprosum recurring events based on immunoglobulin M anti-phenolic glycolipid-1 and cortisol
DOI:
https://doi.org/10.66344/jpad.v28i1.1047Keywords:
ENL, TGF-β, IgM anti-PGL-1, cortisol, leprosy, erythema nodosum leprosumAbstract
Objective To examine the relationship between transforming growth factor (TGF)-β with recurrent erythema nodosum leprosum (ENL) based on the anti-phenolic glycolipid (PGL)-1 IgM antibody and cortisol in leprosy patients.
Methods This research included 44 patients of leprosy MB type; 22 leprosy patients with recurrent ENL reactions as subjects and 22 patients with nonrecurring reaction as controls. We examined the serum levels of TGF-β by ELISA using Human TGF-β Bio legend kit (USA), anti-PGL-1 IgM antibody with the Laboratory of Leprosy Institute of Tropical Disease kit, Airlangga University Surabaya, and cortisol using Stress Xpress Cortisol EIA kit (StressMarq Canada).
Results There were 22 subjects with recurrent ENL reaction (16 male, 6 female, mean age 34.9 year). Mean TGF-β was 62.6 ± 30.4 pg/ml, the IgM anti PGL-1 was 2029 ±1687 µg/ml, and the cortisol was 6.61 ± 1.99 µg/dl, and 22 subjects nonrecurring reaction as controls (15 male, 7 female, mean age 47 year) the mean of TGF-β level was 47.2 ± 23 pg/ml, anti PGL-1 IgM antibody was 629 ±1043 µg/ml and the cortisol was 5.07 ± 2.01 µg/dl. The t-independent statistic test the influence of leprosy MB type group to the recurrent ENL reaction and the un-recurrent ENL patients to TGF-β, IgM anti-PGL-1 and cortisol had p value = 0.015, 0.001 and 0.035 (p <0.05), respectively implying significant difference between subjects and controls. The result of logistic binary test of TGF-β, IgM anti-PGL-1 and cortisol was 0.25, 0.016 and 0.771. This means that IgM anti-PGL-1 has correlation as variable of TGF-β with recurrent ENL.
Conclusion There was significant difference between the levels of TGF-β, anti-PGL-1 IgM antibody and cortisol in leprosy patients with the recurrent ENL reaction and those with nonrecurring ENL reaction. There was a correlation between the levels of TGF-β with recurrent ENL based on the IgM anti-PGL-1. The increasing levels of TGF-β and IgM anti-PGL-1 level on patients with leprosy MB type can be a predictor of the recurrent reaction.
References
1. Fitnes J, Tosh K, Hill AV. Genetics of susceptibility to leprosy. Genes Immun. 2002;3:441-53.
2. Naafs B. Current views on reaction in leprosy. Indian J Lepr. 2000;72:97-122.
3. Fava V, Orlova M, Cobat A, Alcais A, Mira M, Schurr E. Genetic of leprosy reaction: an overview, Mem Inst Oswaldo Cruz. 2012;107 Suppl 1:132-42.
4. Sampaio EP, Oliveira RB, Davies JW, Neto RB, Griffin GE, Shattock RJ. T cell-monocyte contact enhances tumor necrosis factor-alpha production in response to Mycobacterium leprae. J Infect Dis. 2000;182:1463-72.
5. Yamamura M. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science. 1992;255:12.
6. Goulart MB, Mineo JR, Foss MT. Production of transforming growth factor- β1 (TGF-β) by blood monocytes from patient with different clinical forms of leprosy. Clin Exp Immunol. 2000;122:330-4.
7. Gorelik L, Constant S, Flavel RA. Mechanism of transforming growth factor-β induced inhibition of T helper type 1 disorientation. J Exp Med. 2001;195:1499-505.
8. Rojas RE, Demichelis SO, Sarno EN, Eiras AS. IgM anti-phenolic glycolipid I and IgG anti 10-kDp a heat shock protein antibody in sera and immune complexes isolated from leprosy patients with or without erythema nodosum leprosum and contacts. FEMS Immunol Med Microbiol. 1997;19:65-74.
9. Stevani MMA, Martelli CMT, Morais-Neto OL, Martelli P, Costa MB, de Andrade AL. Assessment of anti-PGL-l as a prognostic marker of leprosy reaction. Int J Lepr. 2012;66;356-64.
10. Moura RS, Calado KL, Olivveira MLW, Skula SB. Leprosy serology using PGL-I: a systemic review. Rev Soc Bras Med Trop. 2008;41:11-8.
11. Kar HK, Sharma P, editors. Management of Leprosy Reaction. IAL Textbook of Leprosy, 1st edition. Ne Delhi: Ajanta Offset and Packagings; 2010. P. 387-99.
12. Leal AM, Magalhaes PK, Souza CS, Foss NT. Adrenocortical hormones and interleukin patterns in leprosy. Parasite Immunol. 2003;25:457-61.
13. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003;348:727-34.
14. Guide to eliminate leprosy as public health problem. Geneva: WHO; 2000.
15. Pocaterra L, Jain S, Reddy R. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg. 2006;74:868-79.
16. Jopling WH, editor. Handbook of leprosy, Fifth edn. Delhi: CBs Publisher & Distributor; 1996. P. 82 -91.
17. Manandhar R, Master LJW, Roche PW. Risk factor for erythema nodosum leprosum. Int J Lepr. 1999;67: 270-8.
18. Balagon VF, Gelber RH, Abalos RM, Cellona RV. Reactions following completion of 1 and 2 year multidrug therapy (MDT). Am J Trop Med Hyg. 2010;83:637-44.
19. Kahawita IP, Walker SL, Lockwood DNJ. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg. 2008;102:329-37.
20. Silva EA, Iyer A, Ura S, Lauris JR, Naafs B, Das PK et al. Utility of measuring serum levels of anti PGL-1 antibody, neopterin and c-reactive protein in monitoring leprosy patients during multidrug treatment and reactions. Trop Med and Int Med. 2007;12:1450-8.
21. Zenha EMR, Ferreira MAN, Foss NT. Use of anti-PGL-1antibodies to monitor therapy regimens in leprosy patients. Braz J Med Biol Res. 2009;42:868-97.
22. Rook GAW, Baker W. Cortisol metabolism, cortisol sensitivity and the pathogenesis of leprosy reaction. Trop Med Int Health. 1999;4:493-8.
23. Van Veen NHJ, Lockwood DNJ, Van Brakel WH, Ramirez J Jr, Richardus JH. Intervention for erythema nodosum leprosum. A Cochrane review. Lepr Rev. 2009;80:355-72.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Muhammad Syafei Hamzah
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
